{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:17:42Z","timestamp":1791227862149,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10067-026-08175-y","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:56:23Z","timestamp":1780581383000},"page":"4071-4081","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world efficacy and safety profile of four JAK inhibitors in rheumatoid arthritis: a French single-center observational study"],"prefix":"10.1007","volume":"45","author":[{"given":"Salom\u00e9","family":"Abdellaoui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Al Tabaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Hilliquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"d\u2019Alessandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Hecquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Carv\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Combier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2463-218X","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Avouac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"2","key":"8175_CR1","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.berh.2018.10.005","volume":"32","author":"D van der Woude","year":"2018","unstructured":"van der Woude D, van der Helm-van Mil AHM (2018) Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. Best Pract Res Clin Rheumatol 32(2):174\u2013187","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"8175_CR2","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A et al (2018) Rheumatoid arthritis Nat Rev Dis Primers 4:18001","journal-title":"Rheumatoid arthritis Nat Rev Dis Primers"},{"issue":"10055","key":"8175_CR3","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388(10055):2023\u20132038","journal-title":"Lancet"},{"key":"8175_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106210","volume":"80","author":"P Xin","year":"2020","unstructured":"Xin P, Xu X, Deng C et al (2020) The role of JAK\/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol 80:106210","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"8175_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/ard-2023-223850","volume":"83","author":"M Bonelli","year":"2024","unstructured":"Bonelli M, Kerschbaumer A, Kastrati K et al (2024) Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story. Ann Rheum Dis 83(2):139\u2013160","journal-title":"Ann Rheum Dis"},{"key":"8175_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2022.105454","volume":"89","author":"J Avouac","year":"2022","unstructured":"Avouac J (2022) Where are we with the benefit-risk ratio of JAK inhibitors in rheumatoid arthritis? Joint Bone Spine 89:105454","journal-title":"Joint Bone Spine"},{"issue":"2","key":"8175_CR7","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/ard-2024-226385","volume":"84","author":"J Liu","year":"2025","unstructured":"Liu J, Jiang Y, Zhang S et al (2025) Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial. Ann Rheum Dis 84(2):188\u2013200","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"8175_CR8","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386(4):316\u2013326","journal-title":"N Engl J Med"},{"key":"8175_CR9","unstructured":"European Medicines Agency (EMA) EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. Available at: https:\/\/www.ema.europa.eu\/en\/news\/ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders?utm_source=chatgpt.com. Accessed 26 May 2026"},{"key":"8175_CR10","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (2023) Commission de la transparence \u2013 R\u00e9union du 4 octobre 2023 [Internet]. Available at:\u00a0https:\/\/www.has-sante.fr\/jcms\/p_3485693\/fr\/commission-de-la-transparence-reunion-du-4-octobre-2023?utm_source=chatgpt.com. Accessed 26 May 2026"},{"issue":"13","key":"8175_CR11","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O et al (2016) Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374(13):1243\u20131252","journal-title":"N Engl J Med"},{"issue":"10","key":"8175_CR12","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/rheumatology\/keae012","volume":"63","author":"R Caporali","year":"2024","unstructured":"Caporali R, Taylor PC, Aletaha D et al (2024) Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study. Rheumatology (Oxford) 63(10):2799\u2013809","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"8175_CR13","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40744-022-00529-7","volume":"10","author":"PC Taylor","year":"2023","unstructured":"Taylor PC, Chen YF, Pope J et al (2023) Patient disease trajectories in rheumatoid arthritis patients treated with baricitinib 4-mg in four phase 3 clinical studies. Rheumatol Ther 10(2):463\u2013476","journal-title":"Rheumatol Ther"},{"issue":"10093","key":"8175_CR14","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S et al (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet 390(10093):457\u2013468","journal-title":"Lancet"},{"issue":"10139","key":"8175_CR15","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","volume":"391","author":"GR Burmester","year":"2018","unstructured":"Burmester GR, Kremer JM, Van den Bosch F et al (2018) Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 391(10139):2503\u201312","journal-title":"Lancet"},{"issue":"10139","key":"8175_CR16","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","volume":"391","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Fleischmann R, Combe B et al (2018) Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet 391(10139):2513\u20132524","journal-title":"Lancet"},{"issue":"11","key":"8175_CR17","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","volume":"78","author":"RM Fleischmann","year":"2019","unstructured":"Fleischmann RM, Genovese MC, Enejosa JV et al (2019) Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis 78(11):1454\u20131462","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8175_CR18","first-page":"35","volume":"10","author":"B Combe","year":"2023","unstructured":"Combe B, Besuyen R, Gomez-Centeno A et al (2023) Geographic analysis of the safety and efficacy of filgotinib in rheumatoid arthritis. Rheumatol Ther 10(1):35\u201351","journal-title":"Rheumatol Ther"},{"key":"8175_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003839","author":"PC Taylor","year":"2024","unstructured":"Taylor PC, Kavanaugh A, Nash P et al (2024) Impact of filgotinib on pain control in the phase 3 FINCH studies. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2023-003839","journal-title":"RMD Open"},{"key":"8175_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152572","volume":"69","author":"O Al Tabaa","year":"2024","unstructured":"Al Tabaa O, Hecquet S, Thomas M et al (2024) Real-world assessment of the efficacy and tolerability profile of JAK inhibitors in difficult-to-treat rheumatoid arthritis. Semin Arthritis Rheum 69:152572","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"8175_CR21","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D et al (2017) Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 376(7):652\u2013662","journal-title":"N Engl J Med"},{"issue":"10188","key":"8175_CR22","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P et al (2019) Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet 393(10188):2303\u20132311","journal-title":"Lancet"},{"issue":"4","key":"8175_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.2019.9055","volume":"322","author":"MC Genovese","year":"2019","unstructured":"Genovese MC, Kalunian K, Gottenberg JE et al (2019) Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA 322(4):315\u2013325","journal-title":"JAMA"},{"issue":"5","key":"8175_CR24","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40744-025-00781-7","volume":"12","author":"ML Garcia-Vivar","year":"2025","unstructured":"Garcia-Vivar ML, Prior-Espanol A, Fakhouri W et al (2025) Patient profile and outcomes among patients with rheumatoid arthritis treated with baricitinib versus other therapies in Spain: the RA-BE-REAL study. Rheumatol Ther 12(5):889\u2013907","journal-title":"Rheumatol Ther"},{"key":"8175_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004291","author":"CJ van de Laar","year":"2024","unstructured":"van de Laar CJ, Oude Voshaar MAH, Ten Klooster P et al (2024) PERFECTRA: a pragmatic, multicentre, real-life study comparing treat-to-target strategies with baricitinib versus TNF inhibitors in patients with active rheumatoid arthritis after failure on csDMARDs. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2024-004291","journal-title":"RMD Open"},{"issue":"10","key":"8175_CR26","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1093\/rheumatology\/keac068","volume":"61","author":"A Barbulescu","year":"2022","unstructured":"Barbulescu A, Askling J, Chatzidionysiou K et al (2022) Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data. Rheumatology (Oxford) 61(10):3952\u20133962","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"8175_CR27","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1136\/ard-2023-224670","volume":"83","author":"R Aymon","year":"2024","unstructured":"Aymon R, Mongin D, Bergstra SA et al (2024) Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the \u201cJAK-pot\u201d study). Ann Rheum Dis 83(4):421\u2013428","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"8175_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185x.70458","volume":"28","author":"HB Abacioglu","year":"2025","unstructured":"Abacioglu HB, Colak AF, Yalcinkaya B, Ozcakar L (2025) From silicone to synovitis: autoimmune\/inflammatory syndrome induced by adjuvants (ASIA) in Behcet\u2019s disease. Int J Rheum Dis 28(11):e70458","journal-title":"Int J Rheum Dis"},{"key":"8175_CR29","doi-asserted-by":"publisher","unstructured":"Abacioglu HB, Cetin A (2025) Advanced ultrasonographic insights into neglected\/occult achilles tendon rupture in rheumatoid arthritis. Am J Phys Med Rehabil. https:\/\/doi.org\/10.1097\/PHM.0000000000002929","DOI":"10.1097\/PHM.0000000000002929"},{"key":"8175_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.154273","volume":"241","author":"V Ricci","year":"2023","unstructured":"Ricci V, Ricci C, Tamborrini G et al (2023) From histology to sonography in synovitis: EURO-MUSCULUS\/USPRM approach. Pathol Res Pract 241:154273","journal-title":"Pathol Res Pract"},{"issue":"1","key":"8175_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000428","volume":"3","author":"MA D'Agostino","year":"2017","unstructured":"D\u2019Agostino MA, Terslev L, Aegerter P et al (2017) Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce-Part 1: definition and development of a standardised, consensus-based scoring system. RMD Open 3(1):e000428","journal-title":"RMD Open"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08175-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08175-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08175-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:27:49Z","timestamp":1783398469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08175-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["8175"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08175-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A: Honoraria: Alfasigma, Lilly, Pfizer, Abbvie, Bristol-Myers Squibb, Nordic Pharma, Medac, Novartis, Fresenius Kabi, Janssen and Celltrion. Research grants: Bristol-Myers Squibb, Pfizer (Passerelle), Novartis (Dreamer), Fresenius Kabi, Alfasigma, Nordic Pharma. The other authors have disclosed no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}